EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).

Size: px
Start display at page:

Download "EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9)."

Transcription

1 EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products for Human Use, for management of the Sector Pharmacovigilance and Risk Management: All pharmacovigilance activities at the level of the Agency relating to centrally authorised products for human use, in particular - the EudraVigilance Database and analysis system - signal detection, risk assessment and benefit:risk evaluation throughout the product life-cycle - support to the Committee for Medicinal Products for Human Use (CHMP), other EMEA Scientific Committees, Working Parties, Scientific Advisory Groups, ad hoc expert groups and expert working groups - risk management including communication to the stakeholders (patients, healthcare professionals, pharmaceutical industry and the general public) - crisis management in pharmacovigilance - input to the European Risk Management Strategy and the EMEA Road Map as regards pharmacovigilance and risk management - implementation and further development of the European Network of Centres of Pharmacoepidemiology and Pharmacovigilance (ENCePP) Overall responsibility for the Sector activities, including management of the Sector Staff Collaboration with other Units and Sectors, e.g. the Pre-Authorisation Human Unit regarding risk management, and the Inspections Sector regarding product defects, pharmacovigilance inspections and Good Clinical Practice (GCP) The incumbent will ensure that the objectives and performance measures in relation to the Sector as laid down in the EMEA Work Programme are adhered to, and that cross Unit and cross Sector activities are coordinated Successful candidates are likely to have: Clinical experience and extensive knowledge in the field of pharmacovigilance, including signal detection, and risk management Management skills and managerial experience, including capacity for managing and motivating staff with particular emphasis on the promotion of teamwork, maximisation of efficiency and experience in chairing meetings Good knowledge of pharmacoepidemiology Good knowledge of European pharmaceutical legislation Experience in project management and quality systems implementation/operations Experience in planning and reporting activities Experience in the use of information and communication technologies Diplomatic skills, allowing appropriate liaison with the services of the Community Institutions and with the National Competent Authorities Ability to communicate and present the Agency s position externally and to staff internally Experience in working in a multicultural environment. Essential requirements for this post: 1. A university degree in the field of medicine, pharmacy or other relevant life sciences 2. At least 12 years professional experience after obtaining the relevant degree, that must have been obtained by the closing date, of which at least three years should be relevant to the description of duties outlined above 3. A good command of English and a thorough knowledge of another language of the Communities to the extent necessary for the performance of duties (for any promotion in the future, knowledge of a third language of the Community would be required) For essential requirements 1. and 2. above candidates will be required to provide proof of each

2 EMEA/AD/259: Administrator, Regulatory Affairs and Organisational Support Unit for the Post-Authorisation Evaluation of Medicines for Human Use, (AD 6) With responsibility, under the Head of Sector for Regulatory Affairs and Organisational Support for: Provision of regulatory and procedural advice in relation to the development, evaluation and surveillance of medicinal products for human use, submitted through the Centralised Procedure from early pre-submission to post-authorisation follow up. Provision of regulatory and procedural advice in relation to referrals for Non-Centrally Authorised Products. Provision of regulatory support to the Committee for Medicinal Products for Human Use (CHMP) and its associated Working Parties and expert Groups, the Committee for Orphan Medicinal Products (COMP) and the Paediatric Committee (PDCO) Responsible for ensuring co-ordination in the application and interpretation of legislation to the operations of the EMEA in co-operation with other regulatory affairs/legal colleagues and where necessary the European Commission. Provision of regulatory and procedural guidance in compliance with community legislation to Agency staff, all the Human Scientific Committees and their working parties. Responsible for the development of regulatory and procedural guidance through internal and external Standard Operating Procedures, Guidance documents, etc. Provision of regulatory advice in relation to the new pharmaceutical legislation and development of EMEA policy in emerging topics of interest e.g. borderline products, advanced therapies, pharmacovigilance. Successful candidates are likely to have the following qualifications and background experience in the following areas: Extensive Regulatory Affairs experience in a regulatory agency or in Industry In-depth understanding of Community Legislation in the field of pharmaceuticals Experience of interaction with Industry/Regulatory Authorities Experience in working in a team environment. Excellent written and oral communication skills Experience and knowledge in some of the following areas would be an advantage: Biological and biotech medicinal products, advanced therapies Labelling and product information Multi-disciplinary project management & technical meeting support Experience in working in a multicultural environment Essential requirements for this post are: 1. A university degree in pharmacy, medicine or life sciences 2. At least three years professional experience after obtaining the relevant degree, that must have been obtained by the closing date, relating to the field covered by the above description of duties 3. A good command of English and a thorough knowledge of another language of the Communities to the extent necessary for the performance of duties (for any promotion in the future knowledge of a third language of the Community would be required) For essential requirements 1. and 2. candidates will be required to provide proof of each one prior to the interview stage. 2/8

3 EMEA/AD/260: Administrator in the Medical Information Sector, Unit for the Post- Authorisation Evaluation of Medicines for Human Use (AD 6) With responsibility, under the Head of Sector for Medical Information, for Writing medical information in plain language particularly the European Public Assessment Report (EPAR) summaries; Providing support to other Sectors/Units with regard to the preparation of medical information intended to health care professionals, patients or the general public for publication on the EMEA website such as question-and-answer documents (mainly in Pharmacovigilance field); Provide support on other written documents especially press releases and lines to take and other documents in relation to medical information especially in the area of medicines for children; Contribute to the improvement of the EMEA website with regard to provision of information to the public; Contributing, implementing and adhering to quality assurance system of the EMEA including preparation of guidelines Standard Operational Procedure (SOP) and templates. The successful candidates are likely to have experience and skills in the following areas: Excellent communication/language skills; Good understanding of medicines, pharmaceuticals and the information needs of patients and the general public; Ability to communicate clearly while keeping strictly to the rules; Ability to work effectively within given timeframe; Ability to translate complex information into the right language for the audience, i.e., healthcare professionals, patients or the general public. Experience and knowledge in one or more of the following areas would be an advantage: Understanding of Community legislation in the field of Pharmaceuticals; Working in a team environment; At least three years experience in medical writing Essential requirements for this post: 1. A university degree preferably in the field of life sciences, medicine, pharmacy or languages (e.g. linguistics) 2. At least three years professional experience after obtaining the relevant degree, that must have been obtained by the closing date, in the fields covered by the above description of duties 3. An excellent command of English and a thorough knowledge of at least one other official Community language (for any promotion in the future, knowledge of a third language of the Community would be required) For essential requirements 1. and 2. candidates will be required to provide proof of each one prior to the interview stage. EMEA/AD/261: Administrator (Scientific), EudraVigilance, Unit for the Post-Authorisation Evaluation of Medicines for Human Use (AD6) With responsibility, under the Head of Sector for Pharmacovigilance and Post-Authorisation Safety and Efficacy of Medicines, for Performing customised scientific and administrative database queries and statistics on request of EMEA s Scientific Committees and Working Parties using SAS, Microstrategy and Oracle 3/8

4 Developing business requirements for pharmacovigilance informatics projects Developing customised scientific and administrative database queries and statistics using SAS, Microstrategy and Oracle in order to integrate additional scientific data sets (e.g. THIN) within EudraVigilance Development of statistical methods in relation to the analysis and evaluation of adverse drug reaction data Management of medicinal product information for data analysis Supporting the use of standard terminologies (e.g. MedDRA, MedDRA SMQs, EVMPD) for data analysis and signal detection Preparation of training material and support of training courses for regulators and pharmaceutical industry Preparation of use cases, storyboards, SOPs, WINs and guidelines Liaison with pharmaceutical industry, sponsors of clinical trials and national Competent Authorities regarding all aspects of signal detection and evaluation of pharmacovigilance data Supporting all activities related to the electronic transmission and management of individual case safety reports (ICSRs) in the frame of the EudraVigilance project Duplicate detection and administration in EudraVigilance Recoding administration in EudraVigilance Successful candidates are likely to have: High competence in IT and/or statistics preferably in the area of pharmacovigilance and/or pharmaceuticals Knowledge of the use of statistical software Experience in the use of databases Experience in working in a team environment Good oral and written communication skills Experience and/or sound knowledge in several of the following areas would be an advantage: SAS (including the IML module), Microstrategy and/or Oracle Other statistical software packages MS Access SQL and PL/SQL Data warehouse and data mining tools Three layers IT architectures: database servers(oracle), application servers and web servers Reference data models and ontology Statistical and scientific analysis of pharmacovigilance data Active involvement in implementing a database Pharmacovigilance database use MedDRA Basic understanding of epidemiology ICH E2B(R2)/M2 standards Signal detection in pharmacovigilance or the pharmaceutical/clinical domain Experience in working in a multicultural environment Community procedures related to the various aspects of pharmacovigilance and/or pharmaceuticals Essential requirements for this post are: 1. A university degree in one of the following subjects: statistics, informatics, IT, physics, mathematics, pharmacy, chemistry, pharmaceutical technology or medicine 2. At least three years professional experience, after obtaining the relevant degree in the field, that must have been obtained by the closing date 3. A good command of English and a thorough knowledge of another language of the Communities (for any promotion in the future a third language of the Community would be required) 4/8

5 For essential requirements 1. and 2. candidates will be required to provide proof of each one prior to the interview stage. EMEA/AD/262: Administrator (Scientific), EudraVigilance, Unit for the Post-Authorisation Evaluation of Medicines for Human Use (AD5) With responsibility, under the Head of Sector for Pharmacovigilance and Post-Authorisation Safety and Efficacy of Medicines, for Dealing with requests to access to pharmacovigilance/eudravigilance data Supporting of all pharmacovigilance activities related to the EudraVigilance project Duplicate detection and administration related Individual Case Safety Reports (ICSRs) reported to EudraVigilance Management of medicinal product information in the EudraVigilance Medicinal Product Dictionary (EVMPD) Performance of standardised queries and statistics on request of stakeholders using the EudraVigilance Data Warehouse and Analysis System (EVDAS) Support of signal detection and analysis in EudraVigilance Interaction with stakeholders related to questions in the area of EudraVigilance and pharmacovigilance Writing of guidelines, standard operating procedures, work instructions and training material in relation to EudraVigilance and pharmacovigilance Successful candidates are likely to have: Knowledge of EU pharmacovigilance guidelines and pharmaceutical legislation Knowledge in the area of clinical trials and epidemiology Excellent written and oral communication skills Knowledge in several of the following areas would be an advantage: Professional experience relevant to the description of duties outlined above Signal detection and data analysis in pharmacovigilance Conduct and reporting of epidemiological studies Statistical software packages Information Technology, preferably in the use of a pharmacovigilance or medicinal product database Medicinal product and substance classification and terminologies Essential requirements for this post are: 1. A university degree in pharmacy, chemistry, pharmaceutical technology, medicine, life science, statistics, informatics or IT 2. A good command of English and a thorough knowledge of another language of the Communities to the extent necessary for the performance of duties (for any promotion in the future knowledge of a third language of the Community would be required) For essential requirements 1. and 2. above candidates will be required to provide proof of each EMEA/AST/263: Assistant, Regulatory Affairs and Organisational Support, Unit for the Post- Authorisation Evaluation of Medicines for Human Use, (AST 3) Reporting to the Section Coordinator of the Central Information Group (CIG), providing a support service to both pre and post authorisation Human Units as well as to the Administration Unit working in close collaboration with a number of secretarial and archiving colleagues within the CIG. The specific responsibilities of the position would include the following: 5/8

6 - Primary responsibility for document management concerning all phases in the processing of centralised applications from pre-submission to post authorisation activities. In particular these activities include: - Co-ordinating work within the CIG to ensure systematic preparation of product Master Files in accordance with written procedures and the development of such procedures. - Supervising mail managers to ensure an efficient distribution of all documents received to the relevant contact points within the sectors and to external partners e.g. Marketing Authorisation Holders (MAH), European Commission and National Competent Authorities. - Handling of electronically application documentation (e-ctd) and the development of related procedures and written documentation. - Participation on an as needed basis in pre-submission meetings with future applicants, Marketing Authorisation Holders (MAH) and (Co)-rapporteurs in support of new and post authorisation procedures. - In capacity as financial clerk handling all fee related activities associated with centralised applications in accordance with EMEA Rules of Procedure and Financial Regulations ensuring SI2 (financial database) entries are made to a consistently high level of accuracy. - Liaison with other colleagues in preparation of budget documents concerning the Human Units including the monitoring of expenditure on meetings. - Participation in budgetary planning meetings with Administration and both Human Units. Other responsibilities would include: - Coordinating the Unit s statistics in relation to monthly and 6 monthly sector plans, annual reports and work programme and monthly statistics on fee income - Supporting the work of the SIAMED Administrators to ensure updating of the tracking system with accurate information on ongoing applications - In conjunction with Product Team Leaders co-ordination of the validation of applications received - Preparation of timetables, line listings and other documents in support of Committee for Human Medicinal Products (CHMP ) meetings. - Preparation of letters, faxes, s and transmission of CHMP opinions/assessment reports to applicants, MAHs (Co)-rapporteurs and the European Commission - Provision of ad-hoc support to delegates of CHMP as required - Responsible for supervision of mail managers and document. Successful candidates are likely to have experience and skills in the following areas: - Meticulous approach with excellent organisational ability - Capacity to take initiative with a mature assertive attitude - Strong sense of personal responsibility - Working in a team environment - Good oral and written communication skills. - Experience in working in a Regulatory affairs environment Experience and knowledge in the following areas would be an advantage: - Experience of working in a multicultural environment - Experience of working with electronic document management tools - Experience of working with financial processes Essential requirement for this post are: 1. Post-secondary education diploma, plus six years professional experience or 2. A secondary education certificate giving access to post-secondary education plus three years professional experience (which is the equivalent of the educational requirement in the first indent), plus a further six years experience making a total of nine years professional experience 6/8

7 3. Three years of the professional experience required must be in the fields covered by the above description of duties 4. A good command of English and a thorough knowledge of another language of the Communities (for any promotion in the future a third language of the Community would be required) For essential requirements 1. or 2. and 3. candidates will be required to provide proof of each EMEA/AD/264: Administrator (scientific) Unit for the Pre-Authorisation Evaluation of Medicines for Human Use, Quality of Medicines (AD5) Under the Head of Unit/Head of Sector in the Human Medicine Units Sector Quality of Medicine, in particular for: Providing scientific, technical and administrative support for the assessment of products and other scientific or regulatory projects involving the Agency s committees and groups of experts, managing the procedures of the Centralised Procedure of marketing authorisation and amendments, contributing to the scientific secretariat of Working Parties e.g. Biologics, Blood Products, Vaccines, Cell Therapies. Managing the procedures concerning centralised files and amendments (e.g. variations) thereto, providing scientific, technical and administrative support for projects involving the Agency s committees and groups of experts, liaising with rapporteurs/co-ordinators and coordinating the activities essential to the establishment of objective scientific opinions on medicinal products for human use. Successful candidates are likely to have scientific training in pharmacy or other life sciences with relevance to project management in the above-described activities and to have experience in working in a multicultural environment. Specific training and experience in fields such as biotechnologies, emerging technologies associated with advanced therapies (e.g. cells, gene therapy, tissue engineering and medical devices used in such products, nanotechnologies) would be an advantage. General knowledge in the field of development pharmaceutics, formulations and generic medicinal products including bioequivalence would also be an advantage. Professional experience in the fields mentioned above of three years or more would be an advantage. In addition, general knowledge of Community institutions including the Agency and the pharmaceutical legal framework is expected. Essential requirements for this post: 1. A university degree relevant to the field of pharmacy or other relevant life science 2. A good command of English and a thorough knowledge of another language of the Communities to the extent necessary for the performance of duties (for any promotion in the future knowledge of a third language of the Community would be required) For essential requirements 1. and 2. above candidates will be required to provide proof of each EMEA/AD/265: Administrator, Filemaker developer (AD6) With responsibility, under the Head of Sector for IT, for the: Design, definition, implementation and maintenance of Filemaker databases (currently versions 8.5 and 9, to be migrated to newer versions as released). 7/8

8 Standards for the setting-up and use of the Filemaker development, test and production environments Monitoring, tuning and optimising the Filemaker databases. Successful candidates are likely to have background and experience in the following areas: At least three years of experience of developing in Filemaker, including experience on the latest version 9.x. Full life cycle development experience: Gathering user requirements; Developing prototypes; writing, maintaining and testing programs; Deploying applications; Producing technical documentation; Assisting in user training and support; The candidate will be expected to work independently, to liaise effectively with teams and to have overall good interpersonal skills; Experience of working in a multicultural environment. Experience and background in the following areas would be an advantage: Knowledge of SQL and experience with connecting Filemaker databases to Oracle Supervisory experience Knowledge of XML and Adobe Intelligent Forms Essential requirements for this post: 1. A university degree in the field of IT, Sciences or Engineering 2. At least three years professional experience, after obtaining the relevant degree that must have been obtained by the closing date, in the fields covered by the above description of duties 3. A good command of English and a thorough knowledge of another language of the Communities to the extent necessary for the performance of duties (for any promotion in the future knowledge of a third language of the Community would be required) For essential requirements 1. and 2. above candidates will be required to provide proof of each 8/8

EMA pharmacovigilance system manual

EMA pharmacovigilance system manual 13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000

More information

E2B, Safety databases & Eudravigilance

E2B, Safety databases & Eudravigilance E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE

More information

Role Profile Acting Pharmacovigilance Compliance Assessor, Pharmacovigilance Human Products Monitoring

Role Profile Acting Pharmacovigilance Compliance Assessor, Pharmacovigilance Human Products Monitoring Role Profile Acting Pharmacovigilance Compliance Assessor, Pharmacovigilance Human Products Monitoring ROLE SUMMARY Reporting to the Pharmacovigilance (PV) Manager the Acting Pharmacovigilance Compliance

More information

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of

More information

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board 18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

The European Medicines Agency: a model of patient/consumer interaction

The European Medicines Agency: a model of patient/consumer interaction The European Medicines Agency: a model of patient/consumer interaction V International Conference on patient safety Juan García Burgos Head of Public Information and Stakeholder Networking - Medical Information

More information

Report from the Paediatric Committee on its first anniversary

Report from the Paediatric Committee on its first anniversary European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)

More information

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted

More information

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development

More information

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure 11 December 2017 EMA/821278/2015 Human Medicines Research and Development Support European Medicines Agency pre-authorisation procedural advice for users of the This integrated version has been created

More information

EudraVigilance access policy for medicines for human use

EudraVigilance access policy for medicines for human use 23 August 2011 EMA/759287/2009 corr. Patient Health Protection Draft agreed by the EudraVigilance Expert Working Group December 2007 Consultation with the EudraVigilance Steering Committee February 2008

More information

This video gives an overview of the centralised procedure at the European Medicines Agency

This video gives an overview of the centralised procedure at the European Medicines Agency This video gives an overview of the centralised procedure at the European Medicines Agency In Europe today, all medicines must have a marketing authorisation before they can be used by patients And there

More information

Pharmacovigilance. An agency of the European Union

Pharmacovigilance. An agency of the European Union Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

EU Regulation Review: challenges and opportunities for industry

EU Regulation Review: challenges and opportunities for industry EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general

More information

PROFESSIONAL SERVICES CONSULTANT

PROFESSIONAL SERVICES CONSULTANT 0 PROFESSIONAL SERVICES CONSULTANT Professional Services Consultants have ultimate responsibility for the smooth implementation of systems with our customers, by ensuring the implementation is mapped effectively

More information

Safety Measures in the new Pharmacovigilance System

Safety Measures in the new Pharmacovigilance System Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation

More information

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member

More information

Pharmacovigilance: Information systems and services

Pharmacovigilance: Information systems and services Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver

More information

Procedure management of variations

Procedure management of variations Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European

More information

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities

More information

Summary of the work programme for the. European Medicines Agency

Summary of the work programme for the. European Medicines Agency European Medicines Agency EMEA/MB/44295/26 Summary of the work programme for the European Medicines Agency 27 This document provides a summary of the Agency s work programme 27. The Agency s full work

More information

Clinical Trials application process, legislation & guidelines

Clinical Trials application process, legislation & guidelines Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission

More information

EudraVigilance auditable requirement project

EudraVigilance auditable requirement project 22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation

More information

Saudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority

Saudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and

More information

Questions And Answers To Support The

Questions And Answers To Support The Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted

More information

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE: Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE

More information

INTERNAL VACANCY BULLETIN

INTERNAL VACANCY BULLETIN MARCH 2018 INTERNAL VACANCY BULLETIN GUIDELINES TOAPPLICANTS 1. If you meet the requirements, kindly forward a concise CV to the relevant Practitioner/Administrator (Human Resources) by e-mail or logging

More information

The interface between Good Clinical Practice and Good Manufacturing Practice

The interface between Good Clinical Practice and Good Manufacturing Practice 1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who

More information

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports 24 October 2016 EMA/606369/2012 Rev.15 Procedure Management and Committees Support Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update

More information

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

EudraVigilance Veterinary

EudraVigilance Veterinary 15 September 2011 EMA/13787/2009 STATUS REPORT TO EMA MANAGEMENT BOARD / VETJIG 1 / PHVWP-V 2 / CVMP 3 / HMA-V 4 / CMD-V 5 This document is published on the EVVet Website: http://eudravigilance.ema.europa.eu/veterinary

More information

Five years as EMA Liaison at US FDA

Five years as EMA Liaison at US FDA Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines

More information

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal

More information

Medical Literature Monitoring

Medical Literature Monitoring Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation

More information

Q & A on PSUSA: Guidance document for assessors

Q & A on PSUSA: Guidance document for assessors 31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),

More information

Launching drug product in Europe Q&A

Launching drug product in Europe Q&A Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group Q& Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group

More information

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD) 1 July 2014 EMA/403106/2014 Mandate and objectives for the EMA Working Party on Quality Review of Documents 1. General considerations The European Medicines Agency (EMA) created an ad hoc Working Group

More information

JOB DESCRIPTION. DATE: August 2017 Senior Regulatory Affairs Scientist. Regulatory Affairs Assistant Manager RESPONSIBLE FOR (PEOPLE): N/A

JOB DESCRIPTION. DATE: August 2017 Senior Regulatory Affairs Scientist. Regulatory Affairs Assistant Manager RESPONSIBLE FOR (PEOPLE): N/A JOB DESCRIPTION DATE: August 2017 POSITION: Senior Regulatory Affairs Scientist BUSINESS UNIT: Central Services LOCATION: Craigavon REPORTING TO: Regulatory Affairs Assistant Manager RESPONSIBLE FOR (PEOPLE):

More information

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical

More information

The Revised SmPC Guideline

The Revised SmPC Guideline The Revised SmPC Guideline 1 st June,2010 DIA Regulatory Forum, London Dr. PatrickSALMON SALMON, IMB The Revised SmPC Guideline Reasons for revising the Guideline dl Changes, Implementation and Consequences

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised

More information

Explanatory Note to GVP Module VII

Explanatory Note to GVP Module VII 31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure

More information

Non-clinical Assessment Requirements

Non-clinical Assessment Requirements Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance

More information

Non-clinical documentation Overview of Requirements

Non-clinical documentation Overview of Requirements 3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements

More information

Supporting Innovation through Scientific Advice

Supporting Innovation through Scientific Advice Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are

More information

GMO Technology Conference

GMO Technology Conference GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October

More information

EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP)

EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) European Health Forum - 3 rd October 2013 Falk Ehmann MD, PhD European Medicines Agency - London

More information

Role Profile Pharmacovigilance Assessor, Pharmacovigilance Human Products Monitoring

Role Profile Pharmacovigilance Assessor, Pharmacovigilance Human Products Monitoring Role Profile Pharmacovigilance Assessor, Pharmacovigilance Human Products Monitoring ROLE SUMMARY Reporting to the Pharmacovigilance Manager, the Pharmacovigilance Assessor will work within the Human Products

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,

Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , , Topics Covered: MODULE 1 Introduction To Pharmacovigilance Terminologies used in Pharmacovigilance ADRs Polypharmacy MODULE 2 Pharmacoepidemiology Iatrogenesis Prescription-event monitoring MODULE 3 SAE

More information

Module 1: Administrative information Application form

Module 1: Administrative information Application form 7 September 2017 CMDh/332/2017/Rev.1 User guide for the electronic application form for a Marketing Authorisation Purpose and general rules This User guide has been prepared in order to facilitate the

More information

Pharmacovigilance Officer (m/f) Ref. 2011/10/132

Pharmacovigilance Officer (m/f) Ref. 2011/10/132 Pharmacovigilance Officer (m/f) Ref. 2011/10/132 Our client, a leading European pharmaceutical company is looking to recruit an Pharmacovigilance Officer (m/f) for their Head Office in Luxembourg. Major

More information

Immunization Information System (IIS) Trainer Sample Role Description

Immunization Information System (IIS) Trainer Sample Role Description Immunization Information System (IIS) Trainer Sample Role Description March 2016 0 Note: This role description is meant to offer sample language and a comprehensive list of potential desired responsibilities

More information

Orphan designation in the EU

Orphan designation in the EU Orphan designation in the EU EURORDIS summer school Barcelona, June 2013 Presented by: Jordi Llinares Head of Orphan Medicines An agency of the European Union Outline Overview orphan designation Procedure

More information

EMA. François Houÿez. Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona

EMA. François Houÿez. Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona Patients @ EMA François Houÿez Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona Please comment (fictitious case) A pulmonary hypertension patients organisation collects

More information

INTERNAL VACANCY BULLETIN

INTERNAL VACANCY BULLETIN MARCH 2018 INTERNAL VACANCY BULLETIN GUIDELINES TOAPPLICANTS 1. If you meet the requirements, kindly forward a concise CV to the relevant Practitioner/Administrator (Human Resources) by e-mail or logging

More information

Report to the European Commission on Pharmacovigilance audits carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013

Report to the European Commission on Pharmacovigilance audits carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013 Report to the European Commission on Pharmacovigilance s carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013 1. INTRODUCTION This report provides an overview of the s conducted

More information

ACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm

ACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human

More information

HOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva

HOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva HOT TOPICS IN PV International Society of Pharmacovigilance Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva Dr Irene FERMONT, MD, MSc, EUQPPV ISOP ISRAEL Coordinator

More information

The PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member

The PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member The PRAC Roles and challenges Focus on RMPs and RMAs Prof. Jean-Michel Dogné Head of the Department of Pharmacy PRAC effective member Rue de Bruxelles, 61 B-5000 Namur, Belgium Phone: 0032 (0)81 724289

More information

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for

More information

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations 30 June 2017 EMA/233564/2014 - Rev. 2 Procedure Management and Business Support Division European Medicines Agency practical guidance on the application form for centralised This document is intended as

More information

EUDRAVIGILANCE EXPERT WORKING GROUP (EV-EWG) GUIDELINE ON THE USE OF STATISTICAL SIGNAL DETECTION METHODS IN THE EUDRAVIGILANCE DATA ANALYSIS SYSTEM

EUDRAVIGILANCE EXPERT WORKING GROUP (EV-EWG) GUIDELINE ON THE USE OF STATISTICAL SIGNAL DETECTION METHODS IN THE EUDRAVIGILANCE DATA ANALYSIS SYSTEM European Medicines Agency Evaluation of Medicines for Human Use London, 16 November 2006 Doc. Ref. EMEA/106464/2006 EUDRAVIGILANCE EXPERT WORKING GROUP (EV-EWG) GUIDELINE ON THE USE OF STATISTICAL SIGNAL

More information

IMP Management and Accountability

IMP Management and Accountability This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

ROLE DESCRIPTION. Education Support Officer. For more information, please go to

ROLE DESCRIPTION. Education Support Officer. For more information, please go to ROLE DESCRIPTION Cluster/ Department/ Agency NSW Health Role Number Will Vary Branch/Unit NSW Institute of Psychiatry Classification/Grade/Band Clerk Grade 5-6 Division Academic Role Type Permanent Full

More information

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical

More information

Centralised Procedure and Scientific Advice: an Overview

Centralised Procedure and Scientific Advice: an Overview Centralised Procedure and Scientific Advice: an Overview Andrea Laslop Head of Scientific Office AGES Medizinmarktaufsicht AGES Vienna 30/01/2018 Austrian Federal Office for Safety in Health Care www.basg.gv.at

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

GUIDELINE ON SAFETY AND EFFICACY FOLLOW-UP - RISK MANAGEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS

GUIDELINE ON SAFETY AND EFFICACY FOLLOW-UP - RISK MANAGEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS European Medicines Agency 1 2 3 4 5 6 7 London, 6 th May 2008 Doc. Ref. EMEA/149995/2008 GUIDELINE ON SAFETY AND EFFICACY FOLLOW-UP - RISK MANAGEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS Drafting group

More information

EU Update on Regulatory Developments

EU Update on Regulatory Developments EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation

More information

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure 11 December 2017 EMEA-H-19984/03 Rev. 75 Human Medicines Evaluation Division European Medicines Agency post-authorisation procedural advice for users of the This integrated version has been created for

More information

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical

More information

Inspections: an academic perspective

Inspections: an academic perspective Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk

More information

Financial Controller

Financial Controller Controller Grade: Department: Responsible To: Accountable To: Band 8c Finance Associate Director of Finance Director of Finance Job Summary To deputise for the Associate Director of Finance ( Services)

More information

Guide for National Scientific and Regulatory Advice

Guide for National Scientific and Regulatory Advice Guide for National Scientific and Regulatory Advice ADV-G0017-3 DATE 18 JULY 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS

More information

Monitoring safety of medicines for patients

Monitoring safety of medicines for patients Monitoring safety of medicines for patients Pharmacovigilance activities related to medicines for human use in the EU (COM(2016) 498) Health and Food Safety The information contained in this publication

More information

Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).

Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD). Work instructions Title: Training for signal management leads Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012

More information

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics

More information

Global Clinical Trials in Korea

Global Clinical Trials in Korea Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials

More information

INFORMATION ON JAPANESE REGULATORY AFFAIRS

INFORMATION ON JAPANESE REGULATORY AFFAIRS 2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member

More information

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary

More information

SCOPE Work Package 8 Lifecycle Pharmacovigilance. Risk Management Plan Recommendations

SCOPE Work Package 8 Lifecycle Pharmacovigilance. Risk Management Plan Recommendations Lifecycle Pharmacovigilance Risk Management Plan Recommendations 2016 Lifecycle Pharmacovigilance RMP Recommendations Contents Acknowledgments 3 1. Introduction 4 1.1 Purpose of the document 4 1.2 Definitions

More information

HPRA: Supporting Clinical Research in Ireland

HPRA: Supporting Clinical Research in Ireland HPRA: Supporting Clinical Research in Ireland Lorraine Nolan, Chief Executive, HPRA HRB CRCI launch Gibson Hotel, Dublin September 29 th 2016 Overview HPRA role HPRA Strategic Plan (2016 2020) Quality

More information

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012 New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public

More information

Ethics and Clinical trials EU approach

Ethics and Clinical trials EU approach Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President

More information

E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES

E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES PREPARING FOR E2B(R3) T he electronic transmission of adverse event information to stakeholders, using the International Conference on

More information

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing

More information

Job Description - Director of Human Resources

Job Description - Director of Human Resources Job Description - Director of Human Resources Department: Reports To: Direct Reports: Salary Band: Human Resources Chief Executive & Registrar Human Resources Manager Partner Manager Band A Main Purpose

More information